<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Pathogenesis of antineutrophil cytoplasmic autoantibody-associated vasculitis</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Pathogenesis of antineutrophil cytoplasmic autoantibody-associated vasculitis</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Pathogenesis of antineutrophil cytoplasmic autoantibody-associated vasculitis</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Authors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Ronald J Falk, MD</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Patrick H Nachman, MD, FASN</a></dd><dt><span> </span>Section Editors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Richard J Glassock, MD, MACP</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Gerald B Appel, MD</a></dd><dt><span> </span>Deputy Editors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Albert Q Lam, MD</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Philip Seo, MD, MHS</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> May 15, 2023.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H541413488"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>The antineutrophil cytoplasmic autoantibody (ANCA)-associated vasculitides include granulomatosis with polyangiitis (GPA), microscopic polyangiitis (MPA), and eosinophilic granulomatosis with polyangiitis (EGPA). These vasculitides are complex, immune-mediated disorders in which tissue injury results from the interplay of an initiating inflammatory event and a highly specific immune response. Part of this response is directed against previously shielded epitopes of neutrophil granule proteins, leading to high-titer autoantibodies known as ANCA. The production of ANCA is one of the hallmarks of the ANCA-associated vasculitides. ANCA are directed against antigens present primarily within the granules of neutrophils and monocytes; these autoantibodies produce tissue damage via interactions with primed neutrophils and endothelial cells.</p><p>The pathogenesis of the ANCA-associated vasculitides and the evidence supporting a pathogenetic role for ANCA will be reviewed here. Other aspects of ANCA-associated vasculitis are discussed separately:</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/3060.html" rel="external">"Clinical spectrum of antineutrophil cytoplasmic autoantibodies"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/3117.html" rel="external">"Granulomatosis with polyangiitis and microscopic polyangiitis: Clinical manifestations and diagnosis"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/3105.html" rel="external">"Granulomatosis with polyangiitis and microscopic polyangiitis: Induction and maintenance therapy"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/3040.html" rel="external">"Granulomatosis with polyangiitis and microscopic polyangiitis: Management of relapsing disease"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/3071.html" rel="external">"Granulomatosis with polyangiitis and microscopic polyangiitis: Management of disease resistant to initial therapy"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/4363.html" rel="external">"Epidemiology, pathogenesis, and pathology of eosinophilic granulomatosis with polyangiitis (Churg-Strauss)"</a>.)</p><p></p><p class="headingAnchor" id="H3225705533"><span class="h1">RISK FACTORS AND POSSIBLE INITIATING EVENTS</span><span class="headingEndMark"> — </span>The events leading to the initiation of ANCA-associated vasculitis are not well understood. Genetic factors, infectious agents, a variety of specific drugs, environmental exposures, and other factors may be responsible.</p><p class="headingAnchor" id="H2913497221"><span class="h2">Genetic factors</span><span class="headingEndMark"> — </span>Genome-wide association studies (GWAS) have identified a number of genes associated with susceptibility to ANCA-associated vasculitis. The first GWAS of a large cohort of patients with ANCA-associated vasculitis in Europe revealed associations between patients with proteinase 3 (PR3)-ANCA serotype and genes encoding alpha-1 antitrypsin (<em>SERPINA1</em>, the endogenous inhibitor of PR3), PR3 itself, and human leukocyte antigen (HLA)-DP [<a href="#rid1">1</a>]. Anti-myeloperoxidase (MPO)-ANCA was associated with <em>HLA-DQ</em>. An association between <em>HLA-DPB1*0401</em> and PR3-ANCA-associated vasculitis was also identified in children [<a href="#rid2">2</a>]. </p><p>In addition, the major histocompatibility complex (MHC) class II allele <em>HLA-DRB1*15</em> appears to increase the risk of PR3-associated ANCA vasculitis among African Americans and also contributes to disease risk among White Americans [<a href="#rid3">3</a>], whereas <em>HLA-B55</em> has been associated with ANCA-associated vasculitis in Asian but not in White patients [<a href="#rid4">4</a>]. A single-nucleotide polymorphism in a gene encoding a protein tyrosine phosphatase (<em>PTPN22</em>) has been associated with both ANCA disease and rheumatoid arthritis [<a href="#rid5">5</a>]. Other genetic variants reported to be associated with ANCA-associated vasculitis include <em>CD226</em>, <em>CTLA4</em>, <em>FCGR2A</em>, <em>TLR9</em>, <em>RXRB</em>, and <em>STAT4</em> [<a href="#rid4">4</a>]; <em>BACH2</em> among Scandinavian individuals with MPO-ANCA vasculitis [<a href="#rid6">6</a>]; and <em>ATG7</em> among Chinese individuals with microscopic polyangiitis [<a href="#rid7">7</a>].</p><p><em>HLA-DPB1*0401</em> has been associated with an increased risk of relapse among patients with PR3-ANCA vasculitis, which appears to be driven by the HLA presentation of a specific epitope (PR3225-239) to autoreactive T cells [<a href="#rid8">8</a>]. In addition, variant carriers of a single nucleotide polymorphism, rs62132293, found upstream of the gene encoding PR3 (<em>PRTN3</em>) transcription start site, have been found to have elevated leucocyte <em>PRTN3</em> gene expression compared with noncarriers, a younger age of onset of disease, and an increased risk of relapse compared with patients with MPO-ANCA vasculitis [<a href="#rid9">9</a>]. Together, these findings provide further support for the role of the PR3 antigen itself in the pathogenesis of PR3-ANCA vasculitis. Whether these genetic associations can be utilized clinically to stratify risk of relapse and tailor therapy requires further investigation and confirmation in prospective studies.   </p><p>Studies have also revealed an important role of epigenetic dysregulation in patients who are ANCA positive [<a href="#rid10">10-13</a>]. Patients with active disease appear to have hypomethylated and specific CpG sites when compared with patients who are in remission. In particular, there appears to be a DNA methylation site within PR3 that may be important during periods of active disease. In addition, there is increased autoantigen gene expression in leukocytes in patients with active disease when compared with those who are in remission [<a href="#rid14">14</a>]. There appears to be a positive correlation between expression of the MPO autoantigen and the degree of neutrophil activation [<a href="#rid12">12</a>].</p><p>The role of genetic factors in the pathogenesis of eosinophilic granulomatosis with polyangiitis (EGPA) is discussed separately. (See  <a class="medical medical_review" href="/d/html/4363.html" rel="external">"Epidemiology, pathogenesis, and pathology of eosinophilic granulomatosis with polyangiitis (Churg-Strauss)", section on 'Genetic factors'</a>.)</p><p class="headingAnchor" id="H1848135370"><span class="h2">Environmental factors</span></p><p class="headingAnchor" id="H2141757965"><span class="h3">Infectious agents</span><span class="headingEndMark"> — </span>Because the symptoms of granulomatosis with polyangiitis (GPA) at disease onset overlap substantially with those due to infectious processes, research efforts have focused upon the identification of pathogens that may precipitate GPA in individuals of the proper genetic background. Limited data demonstrating a higher rate of nasal carriage among patients with GPA have implicated <em>Staphylococcus aureus</em> as a possible inciting factor for relapse of GPA [<a href="#rid15">15,16</a>], an effect that may involve the staphylococcal toxic shock syndrome toxin 1 [<a href="#rid17">17</a>]. Functional antibodies directed against lysosome-associated membrane protein 2 (LAMP-2) in patients with ANCA-associated glomerulonephritis have been described and share complete homology with the bacterial adhesion molecule, FimH [<a href="#rid18">18-20</a>].</p><p class="headingAnchor" id="H1122500679"><span class="h3">Drugs</span><span class="headingEndMark"> — </span>A variety of drugs (<a class="drug drug_general" data-topicid="8528" href="/d/drug information/8528.html" rel="external">hydralazine</a>, <a class="drug drug_general" data-topicid="9653" href="/d/drug information/9653.html" rel="external">minocycline</a>, <a class="drug drug_general" data-topicid="9830" href="/d/drug information/9830.html" rel="external">propylthiouracil</a>, levamisole-adulterated cocaine, <a class="drug drug_general" data-topicid="8439" href="/d/drug information/8439.html" rel="external">allopurinol</a>, <a class="drug drug_general" data-topicid="91794" href="/d/drug information/91794.html" rel="external">sofosbuvir</a>, and rifampicin, as examples) have been reported to cause ANCA seroconversion, particularly thiol- and hydrazine-containing compounds. Whether these drugs actually cause a vasculitis is not always clear [<a href="#rid21">21-23</a>], but in some situations, a causal relationship is clear. The majority of these patients have MPO-ANCA; however, many of the patients with levamisole-adulterated, cocaine-associated disease have both MPO- and PR3-ANCA [<a href="#rid22">22</a>]. In addition to MPO-ANCA, patients with hydralazine-associated ANCA vasculitis typically also have anti-histone and anti-nuclear antibodies, and approximately one-third will also have dual ANCA positivity with anti-PR3 antibodies [<a href="#rid24">24</a>]. Hydralazine-associated ANCA is thought to be mediated by a reversal of epigenetic silencing of the MPO and PR3 encoding genes. (See  <a class="medical medical_review" href="/d/html/3060.html" rel="external">"Clinical spectrum of antineutrophil cytoplasmic autoantibodies", section on 'Drug-induced ANCA-associated vasculitis'</a>.)</p><p class="headingAnchor" id="H655962042"><span class="h3">Exposures</span><span class="headingEndMark"> — </span>Given the frequency with which the first symptoms of GPA occur in the respiratory tract, exposure to noninfectious agents or toxins via the inhalational route is another possible inciting event. One such candidate is silica dust. The odds ratio of exposure to silica dust has been reported to be 4.4 times higher for patients with ANCA-associated vasculitis than in a comparison group of patients with kidney disease caused by lupus or other conditions [<a href="#rid25">25</a>]. Another case-control study reported a similarly increased risk of ANCA vasculitis associated with exposure to silica [<a href="#rid26">26</a>], and a meta-analysis of six case-control studies found a significant association of silica exposure with the development of disease [<a href="#rid27">27</a>]. Mercury and lead exposure have also been proposed as potential etiologic agents in the development of GPA [<a href="#rid28">28</a>].</p><p>However, exact relationships between such environmental exposures and vasculitis are complicated by difficulties in obtaining reliable measurements of exposures, the likelihood of recall bias among patients who are diagnosed with ANCA-associated vasculitis, and the choice of appropriate control groups. It is most likely that silica may serve at least as an adjuvant in patients with a predisposition to ANCA-associated vasculitis if it is not a primary trigger.</p><p>Cigarette smoking has also been associated with an increased risk of ANCA-associated vasculitis. In a large case-control study that included 473 patients with ANCA-associated vasculitis (65 percent were MPO-ANCA positive) and 1419 matched controls, smoking was associated with increased odds of having ANCA-associated vasculitis compared with nonsmoking (odds ratio 1.7, 95% CI 1.4-2.2) [<a href="#rid29">29</a>]. This association was particularly strong among patients who were MPO-ANCA positive, and there was a dose-response relationship between cumulative smoking time and risk of ANCA-associated vasculitis.</p><p class="headingAnchor" id="H421685114"><span class="h2">Other factors</span><span class="headingEndMark"> — </span>Other factors that are associated with an increased risk for ANCA-associated vasculitis include the following:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Alpha-1 antitrypsin (A1AT) deficiency</strong> – Because A1AT is the primary in vivo inhibitor of PR3, the observation that patients with A1AT deficiency are at increased risk for GPA suggests a potential pathogenic role in this disease for deficient PR3 clearance from sites of inflammation [<a href="#rid30">30,31</a>]. Decreased local concentrations of A1AT caused by genetic polymorphisms or alterations in the enzyme's functionality induced by inflammation may therefore lead to protease/antiprotease imbalance in the disease microenvironment. Although unproven, these events may be responsible for generating immunogenic forms of PR3 in these patients [<a href="#rid31">31,32</a>]. One study found increased plasma PR3 and A1AT levels in patients with active PR3- or MPO-ANCA vasculitis compared with healthy controls, with, on average, a 3.3-fold higher PR3:A1AT molar ratio [<a href="#rid33">33</a>]. A1AT was shown to prevent the binding of PR3 to the neutrophil surface receptor CD177, thereby reducing neutrophil activation by PR3-ANCA.</p><p></p><p class="headingAnchor" id="H1689018398"><span class="h1">PATHOGENIC ROLE OF ANCA</span></p><p class="headingAnchor" id="H718470683"><span class="h2">Overview of ANCA</span><span class="headingEndMark"> — </span>Approximately 90 percent of patients with granulomatosis with polyangiitis (GPA) have antineutrophil cytoplasmic autoantibodies (ANCA), although the percentage varies according to disease phenotype (patients with limited GPA are less likely to be ANCA positive). Approximately 70 percent of patients with microscopic polyangiitis (MPA) are ANCA positive. By contrast, only 30 to 40 percent of patients with eosinophilic granulomatosis with polyangiitis (EGPA) are ANCA positive.</p><p>The most commonly identified and evaluated autoantigens in GPA and MPA are proteinase 3 (PR3) and myeloperoxidase (MPO). ANCA directed against these antigens are known as MPO-ANCA and PR3-ANCA, respectively. GPA is primarily associated with PR3-ANCA, and MPA is primarily associated with MPO-ANCA; EGPA, when ANCA positive, is almost always associated with MPO-ANCA. Approximately one-third of patients with anti-glomerular basement membrane (GBM) disease have circulating ANCA, with MPO-ANCA accounting for approximately 70 percent of cases [<a href="#rid34">34</a>]. (See  <a class="medical medical_review" href="/d/html/3060.html" rel="external">"Clinical spectrum of antineutrophil cytoplasmic autoantibodies", section on 'Granulomatosis with polyangiitis'</a> and  <a class="medical medical_review" href="/d/html/3060.html" rel="external">"Clinical spectrum of antineutrophil cytoplasmic autoantibodies", section on 'Microscopic polyangiitis'</a> and  <a class="medical medical_review" href="/d/html/3108.html" rel="external">"Anti-GBM (Goodpasture) disease: Pathogenesis, clinical manifestations, and diagnosis", section on 'Double-positive anti-GBM and ANCA-associated disease'</a>.)</p><p>ANCA that target other antigens (eg, lactoferrin, cathepsin G, elastase, and bactericidal/permeability-increasing protein) are frequently observed in immune-mediated disorders not typically associated with vasculitis (eg, ulcerative colitis). These other ANCA are of uncertain clinical and pathological significance. (See  <a class="medical medical_review" href="/d/html/3060.html" rel="external">"Clinical spectrum of antineutrophil cytoplasmic autoantibodies"</a>.)</p><p>Upon immunofluorescence testing of serum using a weak fixative such as ethanol-fixed neutrophils as the substrate, sera containing PR3-ANCA cause a cytoplasmic pattern of neutrophil staining (a "C-ANCA" pattern). By contrast, MPO migrates toward the nucleus, and sera containing MPO-ANCA lead to a perinuclear ("P-ANCA") pattern of staining. For unclear reasons, sera from patients with ANCA-associated vasculitis usually contain either PR3-ANCA or MPO-ANCA, although, occasionally, both may be present. This is most commonly found in drug-induced ANCA-associated vasculitis. (See  <a class="medical medical_review" href="/d/html/3060.html" rel="external">"Clinical spectrum of antineutrophil cytoplasmic autoantibodies", section on 'Drug-induced ANCA-associated vasculitis'</a>.)</p><p>The mechanisms by which ANCA arise and the role of these autoantibodies in causing disease remain unclear. One possibility is that these antibodies are epiphenomena (eg, the byproduct of more primary pathologic processes). However, in the majority of GPA cases and, particularly, in patients with generalized disease, ANCA appear, at minimum, to be involved directly in the widespread tissue damage that is the hallmark of this condition [<a href="#rid35">35-37</a>].</p><p class="headingAnchor" id="H4068048642"><span class="h2">Mechanisms of ANCA production</span><span class="headingEndMark"> — </span>The autoantibody response that produces ANCA is probably generated against newly exposed epitopes (ie, cryptic sites) of the target autoantigen. Following the production of ANCA, the antibody response may generalize to the rest of the molecule or to other components of a macromolecular protein complex via the process of epitope spreading. With ANCA-associated vasculitis, these neoepitopes may arise at the sites of initial tissue injury [<a href="#rid38">38</a>]. Roughly 10 percent of patients lack both MPO-ANCA and PR3-ANCA. A subset of such patients may harbor autoantibodies to other autoantigens; however, one study found that this subset of patients actually does have autoantibodies to MPO that are masked by its endogenous inhibitor, ceruloplasmin [<a href="#rid39">39</a>].</p><p>Epitope specificity appears to be of substantial importance in MPO-ANCA. Several studies have done epitope mapping, suggesting that there are critical epitopes that are important during disease activity that are different than those present in patients in remission or naturally occurring anti-MPO antibodies [<a href="#rid39">39-41</a>]. A specific portion of MPO that is largely hidden appears to be an important target. This MPO epitope-specific region is recognized by human leukocyte antigen (HLA), suggesting that MPO-ANCA patients respond to a restricted region of MPO to which B cells react [<a href="#rid42">42</a>].</p><p>In addition to the human epitope studies, a murine model has suggested that this same region is important in inducing MPO-ANCA autoantibodies in mice [<a href="#rid43">43</a>]. Nasal insufflation of this region of MPO in mice before immunization with MPO resulted in what appears to be the development of immune tolerance [<a href="#rid44">44</a>].</p><p>Antibodies are also generated against complementary peptides that are translated from the antisense RNA that encodes PR3 [<a href="#rid45">45-47</a>]. This has led to the hypothesis that the antigen that initiates the cascade of immunologic events in GPA and related vasculitides is <strong>not</strong> the autoantigen or mimic but the complementary protein of the autoantigen [<a href="#rid46">46,48</a>]. Antibodies to these complementary proteins elicit anti-idiotypic antibodies that may react with the autoantigen or with other unrelated antigens [<a href="#rid47">47,48</a>]. As an example of the latter, antibodies generated to peptides complementary to PR3 also react with plasminogen [<a href="#rid47">47</a>]. This hypothesis was tested and verified in mice with anti-GBM disease using a peptide complementary to the alpha-3 chain of type IV collagen [<a href="#rid49">49</a>].</p><p class="headingAnchor" id="H2947182213"><span class="h2">Evidence for the pathogenicity of ANCA</span><span class="headingEndMark"> — </span>Evidence for the pathogenetic role of ANCA comes from several clinical and preclinical studies:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Animal models</strong> – Two murine models of ANCA-associated vasculitis reveal that adoptive transfer of autoantibody alone is sufficient to induce a necrotizing vasculitis that closely resembles human disease. Development of these models involved two types of genetically altered mice: the MPO knockout mouse and the recombinase-activating gene 2 (RAG-2)-deficient mouse. The latter species lacks both T and B cells.</p><p></p><p class="bulletIndent1">These murine models provide in vivo evidence for the pathogenic potential of ANCA [<a href="#rid50">50</a>]:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>In the first model, MPO knockout mice were initially immunized with mouse MPO, resulting in the formation of anti-MPO splenocytes and anti-MPO antibodies within immunized mice. RAG-2-deficient mice were subsequently injected with either anti-MPO splenocytes or control splenocytes, which did not produce anti-MPO antibodies. RAG-2 mice that received anti-MPO splenocytes developed clinical features of ANCA-associated vasculitis, including crescentic glomerulonephritis and systemic necrotizing vasculitis. By comparison, RAG-2 mice that received non-MPO antibody-producing splenocytes displayed only a relatively mild immune complex glomerulonephritis.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>In the second disease model, RAG-2-deficient and wild-type mice were injected with anti-MPO or control immunoglobulins. Only mice receiving anti-MPO antibodies developed a pauci-immune glomerulonephritis.</p><p></p><p class="bulletIndent1">Another murine model using MPO knockout mice also showed that transplant of MPO bone marrow to MPO-immunized mice resulted in necrotizing crescentic glomerulonephritis [<a href="#rid51">51</a>]. However, transfer of bone marrow that lacked a cysteine protease involved in the activation of enzymes that modulate inflammation appeared to protect mice from glomerulonephritis, suggesting that there is an important role for the activation of neutrophil serine proteases in anti-MPO antibody-induced glomerulonephritis. Of note, the proteasome inhibitor <a class="drug drug_general" data-topicid="8509" href="/d/drug information/8509.html" rel="external">bortezomib</a> post-bone marrow transplantation resulted in disease reduction [<a href="#rid52">52</a>].</p><p></p><p class="bulletIndent1">A rat model of ANCA-associated vasculitis, induced by immunization with human MPO, demonstrated ANCA-mediated enhancement of interactions between leukocytes and the endothelium, thereby supporting the pathogenic role of ANCA [<a href="#rid53">53</a>].</p><p></p><p class="bulletIndent1">The role of T cells has been substantiated by another animal model whereby mice were immunized with MPO and subsequently developed glomerulonephritis; however, this model also required the use of anti-GBM autoantibodies or lipopolysaccharide (LPS) to induce disease [<a href="#rid54">54</a>]. The murine T cell epitope identified in this model overlaps significantly with a major B cell epitope present in patients with active disease [<a href="#rid39">39</a>].</p><p></p><p class="bulletIndent1">With respect to immunopathogenesis and tolerance, animal models comparing MPO-deficient mice and autoimmune regulator (Aire)-deficient mice have also shown that the transcription factor Aire promotes the expression of MPO in the thymus and depletion of regulatory T cells leads to more severe disease [<a href="#rid55">55</a>]. Mast cells are also important in this process, and <a class="drug drug_general" data-topicid="9300" href="/d/drug information/9300.html" rel="external">cromolyn</a> attenuated the vasculitis [<a href="#rid56">56</a>]. Other animal models have highlighted the importance of immunodominant T and B cell epitopes and explored the role of induction of nasal tolerance and injection of tolerogenic dendritic cells in attenuating disease [<a href="#rid43">43,44,57</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Human model</strong> – The first direct evidence in humans that ANCA are pathogenic was provided by a newborn in which the placental transmission of maternal anti-MPO autoantibodies resulted in the pulmonary-renal syndrome [<a href="#rid58">58</a>]. After treatment with glucocorticoids and supportive therapy, the syndrome completely resolved over time in conjunction with the eventual disappearance of maternal ANCA.</p><p></p><p class="headingAnchor" id="H1298186462"><span class="h2">ANCA isotypes and the role of Fc receptors</span><span class="headingEndMark"> — </span>In theory, the isotype of ANCA in a given individual may have pathophysiological importance. Most patients with ANCA-associated vasculitis, for example, produce isotype-switched immunoglobulin G (IgG) ANCA, implying a secondary immune response driven by T cells. However, studies regarding the relative importance of IgG subtypes and other types of ANCA (eg, immunoglobulin M [IgM], immunoglobulin A [IgA]) have been inconclusive and contradictory. At present, there is no conclusive evidence that particular ANCA isotypes influence the susceptibility to or clinical expression of ANCA-associated vasculitis.</p><p>The magnitude of enhanced neutrophil activation by ANCA may also be influenced by antibody specificity for different PR3 epitopes [<a href="#rid28">28,59</a>], IgG subclass, and the type of Fc-gamma receptors (Fc-gamma-Rs) engaged [<a href="#rid60">60-64</a>]. The Fc-gamma-RIIIB allele polymorphism NA1, which allows more efficient neutrophil activation by ANCA, is overrepresented in patients with severe forms of GPA [<a href="#rid65">65,66</a>].</p><p class="headingAnchor" id="H884148872"><span class="h2">ANCA antigens in kidney tissue</span><span class="headingEndMark"> — </span>The emergence of ANCA-associated antigens in the kidney tissue of patients with glomerulonephritis may contribute to the underlying disease process. PR3, MPO, and elastase have been observed within the glomeruli, crescents, and tubular epithelial cells in kidney disorders associated with neutrophilic infiltrates but not in normal kidneys [<a href="#rid67">67,68</a>]. In one study, the extracellular (non-leukocyte associated) glomerular deposition of MPO was found to correlate with glomerular crescent formation and estimated glomerular filtration rate (eGFR) [<a href="#rid69">69</a>]. In a murine model of nephrotoxic nephritis, treatment with a direct MPO inhibitor (AZM198) reduced kidney injury (eg, glomerular thrombosis, proteinuria, and plasma creatinine) compared with vehicle alone but did not reduce glomerular neutrophil infiltration. These results suggested that the protective effect of MPO inhibition may be mediated by a reduction of neutrophil activation and extracellular MPO-mediated inflammation. However, this finding differs from that of a separate model in which reduction in the number of circulating neutrophils was protective, but the use of a direct MPO inhibitor was not [<a href="#rid70">70</a>]. (See <a class="local">'Evidence for the pathogenicity of ANCA'</a> above.)</p><p>In addition to enhancing the antineutrophil activity of ANCA, the proinflammatory activity of tumor necrosis factor (TNF) and other cytokines (such as interleukin [IL] 6) may also contribute directly to kidney injury [<a href="#rid71">71,72</a>]. Local TNF production by infiltrating mononuclear cells and intrinsic kidney cells has been demonstrated in active vasculitic lesions of the kidney in ANCA-positive patients [<a href="#rid72">72</a>]. The mechanism by which these cells become activated to release TNF is unclear.</p><p class="headingAnchor" id="H1649323531"><span class="h1">PATHOGENESIS OF VASCULITIS</span></p><p class="headingAnchor" id="H4097343156"><span class="h2">Neutrophil priming and activation</span><span class="headingEndMark"> — </span>The effects of ANCA are determined by the state of neutrophil activation. Proteinase 3 (PR3) and myeloperoxidase (MPO), located in the cytosol, may be relatively inaccessible to antibody binding. However, neutrophils "primed" with tumor necrosis factor (TNF) as well as those undergoing apoptosis have enhanced expression of membrane-associated PR3 [<a href="#rid36">36,73</a>]. In some individuals, a higher proportion of nonactivated neutrophils may express membrane-associated PR3, which may be a risk factor for vasculitis or more severe manifestations of vasculitis [<a href="#rid74">74</a>]. Genes that encode both PR3 and MPO have been shown to be abnormally upregulated in the peripheral neutrophils of patients with ANCA-associated glomerulonephritis, possibly due to epigenetic silencing defects [<a href="#rid10">10,75</a>].</p><p>Once neutrophils have been activated by priming, ANCA are able to bind relevant membrane-bound antigens [<a href="#rid76">76,77</a>], causing abnormal constitutive activation via either the crosslinking of MPO or PR3 or the binding of Fc receptors [<a href="#rid61">61,62,78,79</a>]. ANCA binding to neutrophils can enhance neutrophil-endothelial cell interactions and subsequent microvascular injury, explaining a possible pathogenetic role for ANCA in systemic vasculitis [<a href="#rid36">36,53</a>].</p><p>The rate at which primed neutrophils degranulate and release chemoattractants and cytotoxic oxygen free-radical species into the local tissue environment is also increased by ANCA [<a href="#rid67">67,80-86</a>]. In addition, primed neutrophils can adhere to and damage vascular endothelial cells and attract additional neutrophils to the site of damage, thereby creating an autoamplifying loop specific to the microenvironment [<a href="#rid73">73,84,85</a>].</p><p>Patients with ANCA-associated vasculitis have increased numbers of primed neutrophils in kidney biopsy specimens as well as increased expression of neutrophil-specific genes, paralleling the activity of the disease [<a href="#rid67">67,87</a>]. In addition, persistent membrane expression of PR3 during periods of disease remission is associated with an increased risk of relapse in granulomatosis with polyangiitis (GPA) patients [<a href="#rid85">85</a>]. Enhanced generation of reactive oxygen species by circulating neutrophils in these patients compared with controls may also occur.</p><p>GPA patients in remission frequently experience disease flares following systemic bacterial or viral infections [<a href="#rid36">36,71</a>]. One potential explanation for this observation is that an infection or other inflammatory process can lead to suprathreshold neutrophil (and, perhaps, monocyte) priming in those individuals with circulating ANCA [<a href="#rid88">88</a>]. This process then sets off the amplifying cascade described above, which ultimately leads to vascular injury. The release of MPO, PR3, elastase, and other proteases from the activated neutrophils can also contribute directly to the local inflammatory process [<a href="#rid71">71</a>].</p><p>ANCA-associated activation may induce neutrophil actin polymerization, resulting in increased neutrophil rigidity [<a href="#rid89">89</a>]. Such activated neutrophils may become sequestered in small-sized vessels since they are unable to adapt morphologically to arterioles; this may help to explain the predilection for small blood vessels in ANCA-associated disease.</p><p class="headingAnchor" id="H2822841975"><span class="h3">NET formation</span><span class="headingEndMark"> — </span>As a killing strategy against invading pathogens, neutrophils release webs of decondensed chromatin called neutrophil extracellular traps (NETs) into the extracellular space [<a href="#rid90">90</a>]. NETs may also contribute to the pathogenesis of ANCA-associated vasculitis [<a href="#rid91">91</a>]. NETs containing PR3 and MPO autoantigens are released by ANCA-stimulated neutrophils and have been demonstrated in the kidneys of patients with ANCA-associated vasculitis [<a href="#rid92">92</a>]. In one study, in vitro NET formation by PR3-ANCA-stimulated neutrophils could be reduced by the addition of a direct MPO inhibitor [<a href="#rid69">69</a>]. Another study found that pharmacologic and genetic inhibition of cyclophilin D (CypD; a mitochondrial matrix protein that controls metabolism and reactive oxygen species production) suppressed ANCA-induced NET formation [<a href="#rid93">93</a>]. In mouse models of ANCA-associated vasculitis, the genetic deletion of CypD ameliorated crescentic glomerulonephritis via the inhibition of CypD-dependent neutrophil and endothelial necrosis.</p><p class="headingAnchor" id="H290485592"><span class="h2">Role of endothelial cells</span><span class="headingEndMark"> — </span>In the early stages of ANCA-associated vasculitis, endothelial cells may recruit inflammatory cells and enhance their adhesion to sites of vascular injury. The subsequent release of PR3 and other neutrophil proteases may induce endothelial synthesis and secretion of interleukin (IL) 8, a potent neutrophil chemoattractant, thereby attracting additional neutrophils [<a href="#rid94">94</a>].</p><p>PR3 released by neutrophils may also enhance the adhesion of accumulating neutrophils and mononuclear cells to the endothelial surface via the induction of adhesion molecules, such as vascular cell adhesion molecule 1 (VCAM-1) [<a href="#rid95">95,96</a>]. The potential significance of adhesion via VCAM-1 is supported by the observation of enhanced in situ expression of this molecule in the affected glomerular tufts of patients with ANCA-associated vasculitis, particularly PR3-ANCA [<a href="#rid97">97,98</a>]. (See  <a class="medical medical_review" href="/d/html/3983.html" rel="external">"Leukocyte-endothelial adhesion in the pathogenesis of inflammation"</a>.)</p><p>Whether endothelial cells produce PR3 and display this molecule upon activation is controversial [<a href="#rid99">99-104</a>]. The contradictory results may be due, in part, to differences in experimental techniques.</p><p>The soluble endothelial protein C receptor binds activated neutrophils via interactions with PR3. This provides a link between neutrophil priming, vascular inflammation, and the coagulation cascade [<a href="#rid105">105</a>] and may explain, in part, the increased risk of venous thrombotic events in GPA [<a href="#rid72">72</a>].</p><p>There is also evidence for organ-specific antiendothelial cell antibodies (AECAs) [<a href="#rid104">104</a>]. The exact antigens and their role in disease development are unclear, but one possible target is the 60 kilodalton heat shock protein, which plays a role in protein assembly [<a href="#rid106">106</a>].</p><p class="headingAnchor" id="H1235130334"><span class="h2">Activation of the alternative complement pathway</span><span class="headingEndMark"> — </span>The alternative complement pathway may play a role in exacerbating and/or perpetuating anti-MPO-associated vasculitis [<a href="#rid107">107</a>]. Transgenic mice expressing human C5a receptor (C5aR) were protected from ANCA-associated vasculitis when given an oral small molecule antagonist of human C5aR called <a class="drug drug_general" data-topicid="133260" href="/d/drug information/133260.html" rel="external">avacopan</a> (also known as CCX168), indicating the importance of the alternative complement pathway in this model [<a href="#rid108">108</a>]. In humans, abnormal levels of C3a, C5a, and soluble C5b-9 have been identified in the plasma, kidneys, and urine of patients with either MPO- or PR3-ANCA-associated disease. Avacopan has been evaluated for the treatment of patients with ANCA-associated vasculitis; these data are discussed elsewhere. (See  <a class="medical medical_review" href="/d/html/3105.html" rel="external">"Granulomatosis with polyangiitis and microscopic polyangiitis: Induction and maintenance therapy", section on 'Avacopan'</a>.)</p><p class="headingAnchor" id="H1442180236"><span class="h2">Role of B cells</span><span class="headingEndMark"> — </span>B cells also play an important role in ANCA-associated vasculitis [<a href="#rid109">109</a>]. In the early 1980s, studies with <a class="drug drug_general" data-topicid="9308" href="/d/drug information/9308.html" rel="external">cyclophosphamide</a> indicated that, among lymphocytes, its greater effect may be upon B cells rather than T cells [<a href="#rid110">110</a>]. Subsequently, it was shown that the number of activated B cells (but not the number of activated T cells) in circulation correlates with disease activity scores in ANCA-associated vasculitis [<a href="#rid111">111</a>]. In addition, large randomized trials have shown that anti-CD20 therapies (that deplete B cells) can induce remission in patients with GPA or microscopic polyangiitis (MPA). (See  <a class="medical medical_review" href="/d/html/3105.html" rel="external">"Granulomatosis with polyangiitis and microscopic polyangiitis: Induction and maintenance therapy", section on 'Induction therapy'</a>.)</p><p>The rationale for why B cell depletion is effective in ANCA-associated vasculitis includes the complete removal or substantial reduction of ANCA production, diminution of the contribution of B cells to antigen presentation and cytokine production, and the inhibition of B cell/T cell crosstalk.</p><p class="headingAnchor" id="H4191610822"><span class="h2">Role of T cells</span><span class="headingEndMark"> — </span>Numerous studies have shown defects in both T regulatory (Treg) and B regulatory cells in patients with active ANCA-associated vasculitis [<a href="#rid112">112</a>]. In particular, while patients have an increased number of Treg cells, these cells appear to possess a diminished suppressive capacity, which may be associated with altered distribution of Treg subsets (increase in CD103<sup>+</sup> and CCR7<sup>+ </sup>and decrease in CXCR3<sup>+</sup> subsets) in patients with active ANCA-associated vasculitis compared with healthy controls [<a href="#rid113">113</a>].</p><p>Since ANCA-associated vasculitis is an antigen-driven process, the disease may heavily depend upon help from T cells. This hypothesis is supported by the finding that mononuclear cells have a significant role in this disorder [<a href="#rid60">60,73,76,114-118</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>Patients with active GPA have much higher levels of CD4+ T cell and monocytic activation than do patients in remission or healthy controls [<a href="#rid114">114-116</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Very high levels of the T helper (Th)1 cytokines TNF-alpha and interferon (IFN)-gamma are also observed in patients with active GPA. Monocytes from these patients release large quantities of IL-12, a major inducer of Th1 cytokines.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Population-based studies of GPA patients reveal a diminished frequency of a major inhibitory cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4) allele [<a href="#rid60">60</a>]. This may contribute to increased T cell activation in these patients.</p><p></p><p>These findings suggest that IL-10, a known antagonist of monocyte activation, may inhibit the Th1 pathway in this disease by impairing the production of IL-12. In one study, for example, IL-10 treatment of peripheral blood mononuclear cells from active GPA patients impaired the production of IFN-gamma in vitro [<a href="#rid114">114</a>].</p><p>Another finding that supports a likely role for cellular immunity in disease pathophysiology is the report of a study of five patients with very low cell surface expression of human leukocyte antigen (HLA) class I molecules (caused by impaired expression of the transporter associated with antigen presentation genes) and with clinical and pathologic findings that resembled GPA [<a href="#rid118">118</a>]. Close examination of the granulomatous lesions revealed a large percentage of activated natural killer cells, a subpopulation of non-major histocompatability complex (MHC)-restricted mononuclear cells. Similar findings suggesting a prominent role for the Th1 lymphocyte pathway and mononuclear cells have been observed in patients with giant cell arteritis.</p><p class="headingAnchor" id="H987522831"><span class="h1">SUMMARY</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Overview </strong>– The antineutrophil cytoplasmic autoantibody (ANCA)-associated vasculitides include granulomatosis with polyangiitis (GPA), microscopic polyangiitis (MPA), and eosinophilic granulomatosis with polyangiitis (EGPA). These vasculitides are complex, immune-mediated disorders in which tissue injury results from the interplay of an initiating inflammatory event and a highly specific immune response. (See <a class="local">'Introduction'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Risk factors </strong>– The risk factors and events leading to the initiation of ANCA-associated vasculitis are not well understood. Genetic factors, infectious agents, a variety of specific drugs, environmental exposures, and other factors may be responsible. (See <a class="local">'Risk factors and possible initiating events'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Pathogenic role of ANCA </strong>– Approximately 90 percent of patients with GPA have ANCA, although the percentage varies according to disease phenotype (patients with limited GPA are less likely to be ANCA positive). Among patients with MPA or EGPA, the percentages of patients who are ANCA positive are approximately 70 and 50 percent, respectively. The most commonly identified and evaluated autoantigens in GPA and MPA are proteinase 3 (PR3) and myeloperoxidase (MPO). (See <a class="local">'Pathogenic role of ANCA'</a> above.)</p><p></p><p class="bulletIndent1">The autoantibody response that produces ANCA is probably generated against newly exposed epitopes (ie, cryptic sites) of the target autoantigen. Following the production of ANCA, the antibody response may generalize to the rest of the molecule or to other components of a macromolecular protein complex via the process of epitope spreading. With ANCA-associated vasculitis, these neoepitopes may arise at the sites of initial tissue injury. (See <a class="local">'Mechanisms of ANCA production'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Pathogenesis of vasculitis </strong>– The effects of ANCA are determined by the state of neutrophil activation. Once neutrophils have been activated by priming, ANCA are able to bind relevant membrane-bound antigens, causing abnormal constitutive activation via either the crosslinking of MPO or PR3 or the binding of Fc receptors. ANCA binding to neutrophils can enhance neutrophil-endothelial cell interactions and subsequent microvascular injury, explaining a possible pathogenetic role for ANCA in systemic vasculitis. (See <a class="local">'Neutrophil priming and activation'</a> above.)</p><p></p><p class="bulletIndent1">In the early stages of ANCA-associated vasculitis, endothelial cells may recruit inflammatory cells and enhance their adhesion to sites of vascular injury. The subsequent release of PR3 and other neutrophil proteases may induce endothelial synthesis and secretion of interleukin (IL) 8, a potent neutrophil chemoattractant, thereby attracting additional neutrophils. Activation of the alternative complement pathway has also been implicated in exacerbating and perpetuating ANCA-associated vasculitis. (See <a class="local">'Role of endothelial cells'</a> above and <a class="local">'Activation of the alternative complement pathway'</a> above.)</p><p></p><p class="bulletIndent1">B cells and T cells also appear to play an important role in ANCA-associated vasculitis. (See <a class="local">'Role of B cells'</a> above and <a class="local">'Role of T cells'</a> above.)</p><p></p><p class="headingAnchor" id="H3136743305"><span class="h1">ACKNOWLEDGMENTS</span><span class="headingEndMark"> — </span>UpToDate thanks John H Stone, MD, MPH, Stuart M Levine, MD, FACP, and William F Pendergraft III, MD, PhD, who contributed to earlier versions of this topic review.</p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Lyons PA, Rayner TF, Trivedi S, et al. Genetically distinct subsets within ANCA-associated vasculitis. N Engl J Med 2012; 367:214.</a></li><li><a class="nounderline abstract_t">Gibson KM, Drögemöller BI, Foell D, et al. Association Between HLA-DPB1 and Antineutrophil Cytoplasmic Antibody-Associated Vasculitis in Children. Arthritis Rheumatol 2023; 75:1048.</a></li><li><a class="nounderline abstract_t">Cao Y, Schmitz JL, Yang J, et al. DRB1*15 allele is a risk factor for PR3-ANCA disease in African Americans. J Am Soc Nephrol 2011; 22:1161.</a></li><li><a class="nounderline abstract_t">Rahmattulla C, Mooyaart AL, van Hooven D, et al. Genetic variants in ANCA-associated vasculitis: a meta-analysis. Ann Rheum Dis 2016; 75:1687.</a></li><li><a class="nounderline abstract_t">Jagiello P, Aries P, Arning L, et al. The PTPN22 620W allele is a risk factor for Wegener's granulomatosis. Arthritis Rheum 2005; 52:4039.</a></li><li><a class="nounderline abstract_t">Dahlqvist J, Ekman D, Sennblad B, et al. Identification and functional characterization of a novel susceptibility locus for small vessel vasculitis with MPO-ANCA. Rheumatology (Oxford) 2022; 61:3461.</a></li><li><a class="nounderline abstract_t">Chu L, Zhong H, Zhu Y, et al. Association of ATG7 gene polymorphisms with microscopic polyangiitis in Chinese individuals. Am J Transl Res 2022; 14:7239.</a></li><li><a class="nounderline abstract_t">Chen DP, McInnis EA, Wu EY, et al. Immunological Interaction of HLA-DPB1 and Proteinase 3 in ANCA Vasculitis is Associated with Clinical Disease Activity. J Am Soc Nephrol 2022; 33:1517.</a></li><li><a class="nounderline abstract_t">Chen DP, Aiello CP, McCoy D, et al. PRTN3 variant correlates with increased autoantigen levels and relapse risk in PR3-ANCA versus MPO-ANCA disease. JCI Insight 2023; 8.</a></li><li><a class="nounderline abstract_t">Ciavatta DJ, Yang J, Preston GA, et al. Epigenetic basis for aberrant upregulation of autoantigen genes in humans with ANCA vasculitis. J Clin Invest 2010; 120:3209.</a></li><li><a class="nounderline abstract_t">Jones BE, Yang J, Muthigi A, et al. Gene-Specific DNA Methylation Changes Predict Remission in Patients with ANCA-Associated Vasculitis. J Am Soc Nephrol 2017; 28:1175.</a></li><li><a class="nounderline abstract_t">McInnis EA, Badhwar AK, Muthigi A, et al. Dysregulation of autoantigen genes in ANCA-associated vasculitis involves alternative transcripts and new protein synthesis. J Am Soc Nephrol 2015; 26:390.</a></li><li><a class="nounderline abstract_t">Yang J, Ge H, Poulton CJ, et al. Histone modification signature at myeloperoxidase and proteinase 3 in patients with anti-neutrophil cytoplasmic autoantibody-associated vasculitis. Clin Epigenetics 2016; 8:85.</a></li><li><a class="nounderline abstract_t">Jones BE, Herrera CA, Agosto-Burgos C, et al. ANCA autoantigen gene expression highlights neutrophil heterogeneity where expression in normal-density neutrophils correlates with ANCA-induced activation. Kidney Int 2020; 98:744.</a></li><li><a class="nounderline abstract_t">Stegeman CA, Tervaert JW, Sluiter WJ, et al. Association of chronic nasal carriage of Staphylococcus aureus and higher relapse rates in Wegener granulomatosis. Ann Intern Med 1994; 120:12.</a></li><li><a class="nounderline abstract_t">Popa ER, Tervaert JW. The relation between Staphylococcus aureus and Wegener's granulomatosis: current knowledge and future directions. Intern Med 2003; 42:771.</a></li><li><a class="nounderline abstract_t">Popa ER, Stegeman CA, Abdulahad WH, et al. Staphylococcal toxic-shock-syndrome-toxin-1 as a risk factor for disease relapse in Wegener's granulomatosis. Rheumatology (Oxford) 2007; 46:1029.</a></li><li><a class="nounderline abstract_t">Kain R, Exner M, Brandes R, et al. Molecular mimicry in pauci-immune focal necrotizing glomerulonephritis. Nat Med 2008; 14:1088.</a></li><li><a class="nounderline abstract_t">Kain R, Matsui K, Exner M, et al. A novel class of autoantigens of anti-neutrophil cytoplasmic antibodies in necrotizing and crescentic glomerulonephritis: the lysosomal membrane glycoprotein h-lamp-2 in neutrophil granulocytes and a related membrane protein in glomerular endothelial cells. J Exp Med 1995; 181:585.</a></li><li><a class="nounderline abstract_t">Peschel A, Basu N, Benharkou A, et al. Autoantibodies to hLAMP-2 in ANCA-negative pauci-immune focal necrotizing GN. J Am Soc Nephrol 2014; 25:455.</a></li><li><a class="nounderline abstract_t">Choi HK, Slot MC, Pan G, et al. Evaluation of antineutrophil cytoplasmic antibody seroconversion induced by minocycline, sulfasalazine, or penicillamine. Arthritis Rheum 2000; 43:2488.</a></li><li><a class="nounderline abstract_t">Pendergraft WF 3rd, Niles JL. Trojan horses: drug culprits associated with antineutrophil cytoplasmic autoantibody (ANCA) vasculitis. Curr Opin Rheumatol 2014; 26:42.</a></li><li><a class="nounderline abstract_t">Pendergraft WF 3rd, Herlitz LC, Thornley-Brown D, et al. Nephrotoxic effects of common and emerging drugs of abuse. Clin J Am Soc Nephrol 2014; 9:1996.</a></li><li><a class="nounderline abstract_t">Santoriello D, Bomback AS, Kudose S, et al. Anti-neutrophil cytoplasmic antibody associated glomerulonephritis complicating treatment with hydralazine. Kidney Int 2021; 100:440.</a></li><li><a class="nounderline abstract_t">Hogan SL, Satterly KK, Dooley MA, et al. Silica exposure in anti-neutrophil cytoplasmic autoantibody-associated glomerulonephritis and lupus nephritis. J Am Soc Nephrol 2001; 12:134.</a></li><li><a class="nounderline abstract_t">Beaudreuil S, Lasfargues G, Lauériere L, et al. Occupational exposure in ANCA-positive patients: a case-control study. Kidney Int 2005; 67:1961.</a></li><li><a class="nounderline abstract_t">Gómez-Puerta JA, Gedmintas L, Costenbader KH. The association between silica exposure and development of ANCA-associated vasculitis: systematic review and meta-analysis. Autoimmun Rev 2013; 12:1129.</a></li><li><a class="nounderline abstract_t">Albert D, Clarkin C, Komoroski J, et al. Wegener's granulomatosis: Possible role of environmental agents in its pathogenesis. Arthritis Rheum 2004; 51:656.</a></li><li><a class="nounderline abstract_t">McDermott G, Fu X, Stone JH, et al. Association of Cigarette Smoking With Antineutrophil Cytoplasmic Antibody-Associated Vasculitis. JAMA Intern Med 2020; 180:870.</a></li><li><a class="nounderline abstract_t">Audrain MA, Sesboüé R, Baranger TA, et al. Analysis of anti-neutrophil cytoplasmic antibodies (ANCA): frequency and specificity in a sample of 191 homozygous (PiZZ) alpha1-antitrypsin-deficient subjects. Nephrol Dial Transplant 2001; 16:39.</a></li><li><a class="nounderline abstract_t">Elzouki AN, Segelmark M, Wieslander J, Eriksson S. Strong link between the alpha 1-antitrypsin PiZ allele and Wegener's granulomatosis. J Intern Med 1994; 236:543.</a></li><li><a class="nounderline abstract_t">Mahr AD, Edberg JC, Stone JH, et al. Alpha₁-antitrypsin deficiency-related alleles Z and S and the risk of Wegener's granulomatosis. Arthritis Rheum 2010; 62:3760.</a></li><li><a class="nounderline abstract_t">Ebert M, Jerke U, Eulenberg-Gustavus C, et al. Protective α1-antitrypsin effects in autoimmune vasculitis are compromised by methionine oxidation. J Clin Invest 2022; 132.</a></li><li><a class="nounderline abstract_t">McAdoo SP, Tanna A, Hrušková Z, et al. Patients double-seropositive for ANCA and anti-GBM antibodies have varied renal survival, frequency of relapse, and outcomes compared to single-seropositive patients. Kidney Int 2017; 92:693.</a></li><li><a class="nounderline abstract_t">Kallenberg CG, Brouwer E, Weening JJ, Tervaert JW. Anti-neutrophil cytoplasmic antibodies: current diagnostic and pathophysiological potential. Kidney Int 1994; 46:1.</a></li><li><a class="nounderline abstract_t">Jennette JC. Pathogenic potential of anti-neutrophil cytoplasmic autoantibodies. Lab Invest 1994; 70:135.</a></li><li><a class="nounderline abstract_t">Jennette JC, Falk RJ. Pathogenesis of antineutrophil cytoplasmic autoantibody-mediated disease. Nat Rev Rheumatol 2014; 10:463.</a></li><li><a class="nounderline abstract_t">Johnson RJ. The mystery of the antineutrophil cytoplasmic antibodies. Am J Kidney Dis 1995; 26:57.</a></li><li><a class="nounderline abstract_t">Roth AJ, Ooi JD, Hess JJ, et al. Epitope specificity determines pathogenicity and detectability in ANCA-associated vasculitis. J Clin Invest 2013; 123:1773.</a></li><li><a class="nounderline abstract_t">Fujii A, Tomizawa K, Arimura Y, et al. Epitope analysis of myeloperoxidase (MPO) specific anti-neutrophil cytoplasmic autoantibodies (ANCA) in MPO-ANCA-associated glomerulonephritis. Clin Nephrol 2000; 53:242.</a></li><li><a class="nounderline abstract_t">Erdbrügger U, Hellmark T, Bunch DO, et al. Mapping of myeloperoxidase epitopes recognized by MPO-ANCA using human-mouse MPO chimers. Kidney Int 2006; 69:1799.</a></li><li><a class="nounderline abstract_t">Free ME, Stember KG, Hess JJ, et al. Restricted myeloperoxidase epitopes drive the adaptive immune response in MPO-ANCA vasculitis. J Autoimmun 2020; 106:102306.</a></li><li><a class="nounderline abstract_t">Ooi JD, Chang J, Hickey MJ, et al. The immunodominant myeloperoxidase T-cell epitope induces local cell-mediated injury in antimyeloperoxidase glomerulonephritis. Proc Natl Acad Sci U S A 2012; 109:E2615.</a></li><li><a class="nounderline abstract_t">Gan PY, Tan DS, Ooi JD, et al. Myeloperoxidase Peptide-Based Nasal Tolerance in Experimental ANCA-Associated GN. J Am Soc Nephrol 2016; 27:385.</a></li><li><a class="nounderline abstract_t">Pendergraft WF 3rd, Preston GA, Shah RR, et al. Autoimmunity is triggered by cPR-3(105-201), a protein complementary to human autoantigen proteinase-3. Nat Med 2004; 10:72.</a></li><li><a class="nounderline abstract_t">Yang J, Bautz DJ, Lionaki S, et al. ANCA patients have T cells responsive to complementary PR-3 antigen. Kidney Int 2008; 74:1159.</a></li><li><a class="nounderline abstract_t">Bautz DJ, Preston GA, Lionaki S, et al. Antibodies with dual reactivity to plasminogen and complementary PR3 in PR3-ANCA vasculitis. J Am Soc Nephrol 2008; 19:2421.</a></li><li><a class="nounderline abstract_t">Pendergraft WF 3rd, Pressler BM, Jennette JC, et al. Autoantigen complementarity: a new theory implicating complementary proteins as initiators of autoimmune disease. J Mol Med (Berl) 2005; 83:12.</a></li><li><a class="nounderline abstract_t">Reynolds J, Preston GA, Pressler BM, et al. Autoimmunity to the alpha 3 chain of type IV collagen in glomerulonephritis is triggered by 'autoantigen complementarity'. J Autoimmun 2015; 59:8.</a></li><li><a class="nounderline abstract_t">Xiao H, Heeringa P, Hu P, et al. Antineutrophil cytoplasmic autoantibodies specific for myeloperoxidase cause glomerulonephritis and vasculitis in mice. J Clin Invest 2002; 110:955.</a></li><li><a class="nounderline abstract_t">Schreiber A, Pham CT, Hu Y, et al. Neutrophil serine proteases promote IL-1β generation and injury in necrotizing crescentic glomerulonephritis. J Am Soc Nephrol 2012; 23:470.</a></li><li><a class="nounderline abstract_t">Bontscho J, Schreiber A, Manz RA, et al. Myeloperoxidase-specific plasma cell depletion by bortezomib protects from anti-neutrophil cytoplasmic autoantibodies-induced glomerulonephritis. J Am Soc Nephrol 2011; 22:336.</a></li><li><a class="nounderline abstract_t">Little MA, Smyth CL, Yadav R, et al. Antineutrophil cytoplasm antibodies directed against myeloperoxidase augment leukocyte-microvascular interactions in vivo. Blood 2005; 106:2050.</a></li><li><a class="nounderline abstract_t">Ooi JD, Gan PY, Chen T, et al. FcγRIIB regulates T-cell autoreactivity, ANCA production, and neutrophil activation to suppress anti-myeloperoxidase glomerulonephritis. Kidney Int 2014; 86:1140.</a></li><li><a class="nounderline abstract_t">Tan DS, Gan PY, O'Sullivan KM, et al. Thymic deletion and regulatory T cells prevent antimyeloperoxidase GN. J Am Soc Nephrol 2013; 24:573.</a></li><li><a class="nounderline abstract_t">Gan PY, Summers SA, Ooi JD, et al. Mast cells contribute to peripheral tolerance and attenuate autoimmune vasculitis. J Am Soc Nephrol 2012; 23:1955.</a></li><li><a class="nounderline abstract_t">Odobasic D, Oudin V, Ito K, et al. Tolerogenic Dendritic Cells Attenuate Experimental Autoimmune Antimyeloperoxidase Glomerulonephritis. J Am Soc Nephrol 2019; 30:2140.</a></li><li><a class="nounderline abstract_t">Schlieben DJ, Korbet SM, Kimura RE, et al. Pulmonary-renal syndrome in a newborn with placental transmission of ANCAs. Am J Kidney Dis 2005; 45:758.</a></li><li><a class="nounderline abstract_t">Sommarin Y, Rasmussen N, Wieslander J. Characterization of monoclonal antibodies to proteinase-3 and application in the study of epitopes for classical anti-neutrophil cytoplasm antibodies. Exp Nephrol 1995; 3:249.</a></li><li><a class="nounderline abstract_t">Zhou Y, Huang D, Paris PL, et al. An analysis of CTLA-4 and proinflammatory cytokine genes in Wegener's granulomatosis. Arthritis Rheum 2004; 50:2645.</a></li><li><a class="nounderline abstract_t">Mulder AH, Heeringa P, Brouwer E, et al. Activation of granulocytes by anti-neutrophil cytoplasmic antibodies (ANCA): a Fc gamma RII-dependent process. Clin Exp Immunol 1994; 98:270.</a></li><li><a class="nounderline abstract_t">Hewins P, Williams JM, Wakelam MJ, Savage CO. Activation of Syk in neutrophils by antineutrophil cytoplasm antibodies occurs via Fcgamma receptors and CD18. J Am Soc Nephrol 2004; 15:796.</a></li><li><a class="nounderline abstract_t">Mulder AH, Stegeman CA, Kallenberg CG. Activation of granulocytes by anti-neutrophil cytoplasmic antibodies (ANCA) in Wegener's granulomatosis: a predominant role for the IgG3 subclass of ANCA. Clin Exp Immunol 1995; 101:227.</a></li><li><a class="nounderline abstract_t">Holland M, Hewins P, Goodall M, et al. Anti-neutrophil cytoplasm antibody IgG subclasses in Wegener's granulomatosis: a possible pathogenic role for the IgG4 subclass. Clin Exp Immunol 2004; 138:183.</a></li><li><a class="nounderline abstract_t">Tse WY, Abadeh S, Jefferis R, et al. Neutrophil FcgammaRIIIb allelic polymorphism in anti-neutrophil cytoplasmic antibody (ANCA)-positive systemic vasculitis. Clin Exp Immunol 2000; 119:574.</a></li><li><a class="nounderline abstract_t">Kocher M, Edberg JC, Fleit HB, Kimberly RP. Antineutrophil cytoplasmic antibodies preferentially engage Fc gammaRIIIb on human neutrophils. J Immunol 1998; 161:6909.</a></li><li><a class="nounderline abstract_t">Falk RJ, Terrell RS, Charles LA, Jennette JC. Anti-neutrophil cytoplasmic autoantibodies induce neutrophils to degranulate and produce oxygen radicals in vitro. Proc Natl Acad Sci U S A 1990; 87:4115.</a></li><li><a class="nounderline abstract_t">Mrowka C, Csernok E, Gross WL, et al. Distribution of the granulocyte serine proteinases proteinase 3 and elastase in human glomerulonephritis. Am J Kidney Dis 1995; 25:253.</a></li><li><a class="nounderline abstract_t">Antonelou M, Michaëlsson E, Evans RDR, et al. Therapeutic Myeloperoxidase Inhibition Attenuates Neutrophil Activation, ANCA-Mediated Endothelial Damage, and Crescentic GN. J Am Soc Nephrol 2020; 31:350.</a></li><li><a class="nounderline abstract_t">Florez-Barros F, Bearder S, Kull B, et al. Myeloid expression of the anti-apoptotic protein Mcl1 is required in anti-myeloperoxidase vasculitis but myeloperoxidase inhibition is not protective. Kidney Int 2023; 103:134.</a></li><li><a class="nounderline abstract_t">Arimura Y, Minoshima S, Kamiya Y, et al. Serum myeloperoxidase and serum cytokines in anti-myeloperoxidase antibody-associated glomerulonephritis. Clin Nephrol 1993; 40:256.</a></li><li><a class="nounderline abstract_t">Noronha IL, Krüger C, Andrassy K, et al. In situ production of TNF-alpha, IL-1 beta and IL-2R in ANCA-positive glomerulonephritis. Kidney Int 1993; 43:682.</a></li><li><a class="nounderline abstract_t">Masutani K, Tokumoto M, Nakashima H, et al. Strong polarization toward Th1 immune response in ANCA-associated glomerulonephritis. Clin Nephrol 2003; 59:395.</a></li><li><a class="nounderline abstract_t">Schreiber A, Otto B, Ju X, et al. Membrane proteinase 3 expression in patients with Wegener's granulomatosis and in human hematopoietic stem cell-derived neutrophils. J Am Soc Nephrol 2005; 16:2216.</a></li><li><a class="nounderline abstract_t">Yang JJ, Pendergraft WF, Alcorta DA, et al. Circumvention of normal constraints on granule protein gene expression in peripheral blood neutrophils and monocytes of patients with antineutrophil cytoplasmic autoantibody-associated glomerulonephritis. J Am Soc Nephrol 2004; 15:2103.</a></li><li><a class="nounderline abstract_t">Ewert BH, Jennette JC, Falk RJ. Anti-myeloperoxidase antibodies stimulate neutrophils to damage human endothelial cells. Kidney Int 1992; 41:375.</a></li><li><a class="nounderline abstract_t">Van Rossum AP, van der Geld YM, Limburg PC, Kallenberg CG. Human anti-neutrophil cytoplasm autoantibodies to proteinase 3 (PR3-ANCA) bind to neutrophils. Kidney Int 2005; 68:537.</a></li><li><a class="nounderline abstract_t">Kettritz R, Jennette JC, Falk RJ. Crosslinking of ANCA-antigens stimulates superoxide release by human neutrophils. J Am Soc Nephrol 1997; 8:386.</a></li><li><a class="nounderline abstract_t">Porges AJ, Redecha PB, Kimberly WT, et al. Anti-neutrophil cytoplasmic antibodies engage and activate human neutrophils via Fc gamma RIIa. J Immunol 1994; 153:1271.</a></li><li><a class="nounderline abstract_t">Brouwer E, Huitema MG, Mulder AH, et al. Neutrophil activation in vitro and in vivo in Wegener's granulomatosis. Kidney Int 1994; 45:1120.</a></li><li><a class="nounderline abstract_t">Cockwell P, Brooks CJ, Adu D, Savage CO. Interleukin-8: A pathogenetic role in antineutrophil cytoplasmic autoantibody-associated glomerulonephritis. Kidney Int 1999; 55:852.</a></li><li><a class="nounderline abstract_t">Kettritz R, Choi M, Butt W, et al. Phosphatidylinositol 3-kinase controls antineutrophil cytoplasmic antibodies-induced respiratory burst in human neutrophils. J Am Soc Nephrol 2002; 13:1740.</a></li><li><a class="nounderline abstract_t">Schreiber A, Luft FC, Kettritz R. Membrane proteinase 3 expression and ANCA-induced neutrophil activation. Kidney Int 2004; 65:2172.</a></li><li><a class="nounderline abstract_t">Pendergraft WF 3rd, Rudolph EH, Falk RJ, et al. Proteinase 3 sidesteps caspases and cleaves p21(Waf1/Cip1/Sdi1) to induce endothelial cell apoptosis. Kidney Int 2004; 65:75.</a></li><li><a class="nounderline abstract_t">Rarok AA, Stegeman CA, Limburg PC, Kallenberg CG. Neutrophil membrane expression of proteinase 3 (PR3) is related to relapse in PR3-ANCA-associated vasculitis. J Am Soc Nephrol 2002; 13:2232.</a></li><li><a class="nounderline abstract_t">Williams JM, Savage CO. Characterization of the regulation and functional consequences of p21ras activation in neutrophils by antineutrophil cytoplasm antibodies. J Am Soc Nephrol 2005; 16:90.</a></li><li><a class="nounderline abstract_t">Alcorta DA, Barnes DA, Dooley MA, et al. Leukocyte gene expression signatures in antineutrophil cytoplasmic autoantibody and lupus glomerulonephritis. Kidney Int 2007; 72:853.</a></li><li><a class="nounderline abstract_t">Nowack R, Schwalbe K, Flores-Suárez LF, et al. Upregulation of CD14 and CD18 on monocytes In vitro by antineutrophil cytoplasmic autoantibodies. J Am Soc Nephrol 2000; 11:1639.</a></li><li><a class="nounderline abstract_t">Tse WY, Nash GB, Hewins P, et al. ANCA-induced neutrophil F-actin polymerization: implications for microvascular inflammation. Kidney Int 2005; 67:130.</a></li><li><a class="nounderline abstract_t">Papayannopoulos V, Zychlinsky A. NETs: a new strategy for using old weapons. Trends Immunol 2009; 30:513.</a></li><li><a class="nounderline abstract_t">Nakazawa D, Tomaru U, Suzuki A, et al. Abnormal conformation and impaired degradation of propylthiouracil-induced neutrophil extracellular traps: implications of disordered neutrophil extracellular traps in a rat model of myeloperoxidase antineutrophil cytoplasmic antibody-associated vasculitis. Arthritis Rheum 2012; 64:3779.</a></li><li><a class="nounderline abstract_t">Kessenbrock K, Krumbholz M, Schönermarck U, et al. Netting neutrophils in autoimmune small-vessel vasculitis. Nat Med 2009; 15:623.</a></li><li><a class="nounderline abstract_t">Kudo T, Nakazawa D, Watanabe-Kusunoki K, et al. Regulation of NETosis and Inflammation by Cyclophilin D in Myeloperoxidase-Positive Antineutrophil Cytoplasmic Antibody-Associated Vasculitis. Arthritis Rheumatol 2023; 75:71.</a></li><li><a class="nounderline abstract_t">Berger SP, Seelen MA, Hiemstra PS, et al. Proteinase 3, the major autoantigen of Wegener's granulomatosis, enhances IL-8 production by endothelial cells in vitro. J Am Soc Nephrol 1996; 7:694.</a></li><li><a class="nounderline abstract_t">Mayet WJ, Meyer zum Büschenfelde KH. Antibodies to proteinase 3 increase adhesion of neutrophils to human endothelial cells. Clin Exp Immunol 1993; 94:440.</a></li><li><a class="nounderline abstract_t">Mayet WJ, Schwarting A, Orth T, et al. Antibodies to proteinase 3 mediate expression of vascular cell adhesion molecule-1 (VCAM-1). Clin Exp Immunol 1996; 103:259.</a></li><li><a class="nounderline abstract_t">Rastaldi MP, Ferrario F, Tunesi S, et al. Intraglomerular and interstitial leukocyte infiltration, adhesion molecules, and interleukin-1 alpha expression in 15 cases of antineutrophil cytoplasmic autoantibody-associated renal vasculitis. Am J Kidney Dis 1996; 27:48.</a></li><li><a class="nounderline abstract_t">Arrizabalaga P, Solé M, Iglesias C, et al. Renal expression of ICAM-1 and VCAM-1 in ANCA-associated glomerulonephritis--are there differences among serologic subgroups? Clin Nephrol 2006; 65:79.</a></li><li><a class="nounderline abstract_t">Mayet WJ, Csernok E, Szymkowiak C, et al. Human endothelial cells express proteinase 3, the target antigen of anticytoplasmic antibodies in Wegener's granulomatosis. Blood 1993; 82:1221.</a></li><li><a class="nounderline abstract_t">King WJ, Adu D, Daha MR, et al. Endothelial cells and renal epithelial cells do not express the Wegener's autoantigen, proteinase 3. Clin Exp Immunol 1995; 102:98.</a></li><li><a class="nounderline abstract_t">De Bandt M, Meyer O, Dacosta L, et al. Anti-proteinase-3 (PR3) antibodies (C-ANCA) recognize various targets on the human umbilical vein endothelial cell (HUVEC) membrane. Clin Exp Immunol 1999; 115:362.</a></li><li><a class="nounderline abstract_t">Pendergraft WF, Alcorta DA, Segelmark M, et al. ANCA antigens, proteinase 3 and myeloperoxidase, are not expressed in endothelial cells. Kidney Int 2000; 57:1981.</a></li><li><a class="nounderline abstract_t">Tervaert JW. Proteinase 3: A cofactor for the binding of antineutrophil cytoplasm antibodies (ANCA) to endothelial cells? Kidney Int 2000; 57:2171.</a></li><li><a class="nounderline abstract_t">Holmén C, Christensson M, Pettersson E, et al. Wegener's granulomatosis is associated with organ-specific antiendothelial cell antibodies. Kidney Int 2004; 66:1049.</a></li><li><a class="nounderline abstract_t">Kurosawa S, Esmon CT, Stearns-Kurosawa DJ. The soluble endothelial protein C receptor binds to activated neutrophils: involvement of proteinase-3 and CD11b/CD18. J Immunol 2000; 165:4697.</a></li><li><a class="nounderline abstract_t">Jamin C, Dugué C, Alard JE, et al. Induction of endothelial cell apoptosis by the binding of anti-endothelial cell antibodies to Hsp60 in vasculitis-associated systemic autoimmune diseases. Arthritis Rheum 2005; 52:4028.</a></li><li><a class="nounderline abstract_t">Kallenberg CG, Heeringa P. Complement system activation in ANCA vasculitis: A translational success story? Mol Immunol 2015; 68:53.</a></li><li><a class="nounderline abstract_t">Xiao H, Dairaghi DJ, Powers JP, et al. C5a receptor (CD88) blockade protects against MPO-ANCA GN. J Am Soc Nephrol 2014; 25:225.</a></li><li><a class="nounderline abstract_t">Pallan L, Savage CO, Harper L. ANCA-associated vasculitis: from bench research to novel treatments. Nat Rev Nephrol 2009; 5:278.</a></li><li><a class="nounderline abstract_t">Cupps TR, Edgar LC, Fauci AS. Suppression of human B lymphocyte function by cyclophosphamide. J Immunol 1982; 128:2453.</a></li><li><a class="nounderline abstract_t">Popa ER, Stegeman CA, Bos NA, et al. Differential B- and T-cell activation in Wegener's granulomatosis. J Allergy Clin Immunol 1999; 103:885.</a></li><li><a class="nounderline abstract_t">von Borstel A, Sanders JS, Rutgers A, et al. Cellular immune regulation in the pathogenesis of ANCA-associated vasculitides. Autoimmun Rev 2018; 17:413.</a></li><li><a class="nounderline abstract_t">Agosto-Burgos C, Wu EY, Iannone MA, et al. The frequency of Treg subsets distinguishes disease activity in ANCA vasculitis. Clin Transl Immunology 2022; 11:e1428.</a></li><li><a class="nounderline abstract_t">Lúdvíksson BR, Sneller MC, Chua KS, et al. Active Wegener's granulomatosis is associated with HLA-DR+ CD4+ T cells exhibiting an unbalanced Th1-type T cell cytokine pattern: reversal with IL-10. J Immunol 1998; 160:3602.</a></li><li><a class="nounderline abstract_t">Muller Kobold AC, Kallenberg CG, Tervaert JW. Monocyte activation in patients with Wegener's granulomatosis. Ann Rheum Dis 1999; 58:237.</a></li><li><a class="nounderline abstract_t">Marinaki S, Kälsch AI, Grimminger P, et al. Persistent T-cell activation and clinical correlations in patients with ANCA-associated systemic vasculitis. Nephrol Dial Transplant 2006; 21:1825.</a></li><li><a class="nounderline abstract_t">Abdulahad WH, van der Geld YM, Stegeman CA, Kallenberg CG. Persistent expansion of CD4+ effector memory T cells in Wegener's granulomatosis. Kidney Int 2006; 70:938.</a></li><li><a class="nounderline abstract_t">Moins-Teisserenc HT, Gadola SD, Cella M, et al. Association of a syndrome resembling Wegener's granulomatosis with low surface expression of HLA class-I molecules. Lancet 1999; 354:1598.</a></li></ol></div><div id="topicVersionRevision">Topic 3074 Version 35.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22808956" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Genetically distinct subsets within ANCA-associated vasculitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/36530128" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Association Between HLA-DPB1 and Antineutrophil Cytoplasmic Antibody-Associated Vasculitis in Children.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21617122" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : DRB1*15 allele is a risk factor for PR3-ANCA disease in African Americans.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26443607" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Genetic variants in ANCA-associated vasculitis: a meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16320352" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : The PTPN22 620W allele is a risk factor for Wegener's granulomatosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34888651" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Identification and functional characterization of a novel susceptibility locus for small vessel vasculitis with MPO-ANCA.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/36398269" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Association of ATG7 gene polymorphisms with microscopic polyangiitis in Chinese individuals.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35672132" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Immunological Interaction of HLA-DPB1 and Proteinase 3 in ANCA Vasculitis is Associated with Clinical Disease Activity.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/36626226" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : PRTN3 variant correlates with increased autoantigen levels and relapse risk in PR3-ANCA versus MPO-ANCA disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20714105" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Epigenetic basis for aberrant upregulation of autoantigen genes in humans with ANCA vasculitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27821628" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Gene-Specific DNA Methylation Changes Predict Remission in Patients with ANCA-Associated Vasculitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25060059" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Dysregulation of autoantigen genes in ANCA-associated vasculitis involves alternative transcripts and new protein synthesis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27752292" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Histone modification signature at myeloperoxidase and proteinase 3 in patients with anti-neutrophil cytoplasmic autoantibody-associated vasculitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32446935" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : ANCA autoantigen gene expression highlights neutrophil heterogeneity where expression in normal-density neutrophils correlates with ANCA-induced activation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8250451" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Association of chronic nasal carriage of Staphylococcus aureus and higher relapse rates in Wegener granulomatosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14518661" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : The relation between Staphylococcus aureus and Wegener's granulomatosis: current knowledge and future directions.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17409134" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Staphylococcal toxic-shock-syndrome-toxin-1 as a risk factor for disease relapse in Wegener's granulomatosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18836458" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Molecular mimicry in pauci-immune focal necrotizing glomerulonephritis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7836914" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : A novel class of autoantigens of anti-neutrophil cytoplasmic antibodies in necrotizing and crescentic glomerulonephritis: the lysosomal membrane glycoprotein h-lamp-2 in neutrophil granulocytes and a related membrane protein in glomerular endothelial cells.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24203998" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Autoantibodies to hLAMP-2 in ANCA-negative pauci-immune focal necrotizing GN.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11083272" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Evaluation of antineutrophil cytoplasmic antibody seroconversion induced by minocycline, sulfasalazine, or penicillamine.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24276086" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Trojan horses: drug culprits associated with antineutrophil cytoplasmic autoantibody (ANCA) vasculitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25035273" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Nephrotoxic effects of common and emerging drugs of abuse.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33857570" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Anti-neutrophil cytoplasmic antibody associated glomerulonephritis complicating treatment with hydralazine.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11134259" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Silica exposure in anti-neutrophil cytoplasmic autoantibody-associated glomerulonephritis and lupus nephritis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15840044" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Occupational exposure in ANCA-positive patients: a case-control study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23820041" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : The association between silica exposure and development of ANCA-associated vasculitis: systematic review and meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15334441" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Wegener's granulomatosis: Possible role of environmental agents in its pathogenesis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32282021" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Association of Cigarette Smoking With Antineutrophil Cytoplasmic Antibody-Associated Vasculitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11208991" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Analysis of anti-neutrophil cytoplasmic antibodies (ANCA): frequency and specificity in a sample of 191 homozygous (PiZZ) alpha1-antitrypsin-deficient subjects.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7964431" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Strong link between the alpha 1-antitrypsin PiZ allele and Wegener's granulomatosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20827781" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Alpha₁-antitrypsin deficiency-related alleles Z and S and the risk of Wegener's granulomatosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/36125911" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Protectiveα1-antitrypsin effects in autoimmune vasculitis are compromised by methionine oxidation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28506760" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Patients double-seropositive for ANCA and anti-GBM antibodies have varied renal survival, frequency of relapse, and outcomes compared to single-seropositive patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7933826" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Anti-neutrophil cytoplasmic antibodies: current diagnostic and pathophysiological potential.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8139256" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Pathogenic potential of anti-neutrophil cytoplasmic autoantibodies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25003769" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : Pathogenesis of antineutrophil cytoplasmic autoantibody-mediated disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7611269" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : The mystery of the antineutrophil cytoplasmic antibodies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23549081" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : Epitope specificity determines pathogenicity and detectability in ANCA-associated vasculitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10809410" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : Epitope analysis of myeloperoxidase (MPO) specific anti-neutrophil cytoplasmic autoantibodies (ANCA) in MPO-ANCA-associated glomerulonephritis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16557221" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : Mapping of myeloperoxidase epitopes recognized by MPO-ANCA using human-mouse MPO chimers.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31383567" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : Restricted myeloperoxidase epitopes drive the adaptive immune response in MPO-ANCA vasculitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22955884" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : The immunodominant myeloperoxidase T-cell epitope induces local cell-mediated injury in antimyeloperoxidase glomerulonephritis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26047792" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : Myeloperoxidase Peptide-Based Nasal Tolerance in Experimental ANCA-Associated GN.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14661018" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : Autoimmunity is triggered by cPR-3(105-201), a protein complementary to human autoantigen proteinase-3.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18596726" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : ANCA patients have T cells responsive to complementary PR-3 antigen.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18701607" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : Antibodies with dual reactivity to plasminogen and complementary PR3 in PR3-ANCA vasculitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15592920" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : Autoantigen complementarity: a new theory implicating complementary proteins as initiators of autoimmune disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25841937" id="rid48" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>49 : Autoimmunity to the alpha 3 chain of type IV collagen in glomerulonephritis is triggered by 'autoantigen complementarity'.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12370273" id="rid49" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>50 : Antineutrophil cytoplasmic autoantibodies specific for myeloperoxidase cause glomerulonephritis and vasculitis in mice.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22241891" id="rid50" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>51 : Neutrophil serine proteases promote IL-1βgeneration and injury in necrotizing crescentic glomerulonephritis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21233415" id="rid51" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>52 : Myeloperoxidase-specific plasma cell depletion by bortezomib protects from anti-neutrophil cytoplasmic autoantibodies-induced glomerulonephritis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15933057" id="rid52" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>53 : Antineutrophil cytoplasm antibodies directed against myeloperoxidase augment leukocyte-microvascular interactions in vivo.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24869670" id="rid53" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>54 : FcγRIIB regulates T-cell autoreactivity, ANCA production, and neutrophil activation to suppress anti-myeloperoxidase glomerulonephritis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23393320" id="rid54" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>55 : Thymic deletion and regulatory T cells prevent antimyeloperoxidase GN.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23138486" id="rid55" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>56 : Mast cells contribute to peripheral tolerance and attenuate autoimmune vasculitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31444274" id="rid56" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>57 : Tolerogenic Dendritic Cells Attenuate Experimental Autoimmune Antimyeloperoxidase Glomerulonephritis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15806479" id="rid57" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>58 : Pulmonary-renal syndrome in a newborn with placental transmission of ANCAs.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8590038" id="rid58" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>59 : Characterization of monoclonal antibodies to proteinase-3 and application in the study of epitopes for classical anti-neutrophil cytoplasm antibodies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15334480" id="rid59" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>60 : An analysis of CTLA-4 and proinflammatory cytokine genes in Wegener's granulomatosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7955533" id="rid60" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>61 : Activation of granulocytes by anti-neutrophil cytoplasmic antibodies (ANCA): a Fc gamma RII-dependent process.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14978183" id="rid61" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>62 : Activation of Syk in neutrophils by antineutrophil cytoplasm antibodies occurs via Fcgamma receptors and CD18.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7648707" id="rid62" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>63 : Activation of granulocytes by anti-neutrophil cytoplasmic antibodies (ANCA) in Wegener's granulomatosis: a predominant role for the IgG3 subclass of ANCA.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15373923" id="rid63" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>64 : Anti-neutrophil cytoplasm antibody IgG subclasses in Wegener's granulomatosis: a possible pathogenic role for the IgG4 subclass.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10691933" id="rid64" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>65 : Neutrophil FcgammaRIIIb allelic polymorphism in anti-neutrophil cytoplasmic antibody (ANCA)-positive systemic vasculitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9862724" id="rid65" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>66 : Antineutrophil cytoplasmic antibodies preferentially engage Fc gammaRIIIb on human neutrophils.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2161532" id="rid66" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>67 : Anti-neutrophil cytoplasmic autoantibodies induce neutrophils to degranulate and produce oxygen radicals in vitro.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7847352" id="rid67" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>68 : Distribution of the granulocyte serine proteinases proteinase 3 and elastase in human glomerulonephritis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31879336" id="rid68" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>69 : Therapeutic Myeloperoxidase Inhibition Attenuates Neutrophil Activation, ANCA-Mediated Endothelial Damage, and Crescentic GN.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/36154801" id="rid69" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>70 : Myeloid expression of the anti-apoptotic protein Mcl1 is required in anti-myeloperoxidase vasculitis but myeloperoxidase inhibition is not protective.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8281714" id="rid70" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>71 : Serum myeloperoxidase and serum cytokines in anti-myeloperoxidase antibody-associated glomerulonephritis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8455368" id="rid71" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>72 : In situ production of TNF-alpha, IL-1 beta and IL-2R in ANCA-positive glomerulonephritis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12834170" id="rid72" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>73 : Strong polarization toward Th1 immune response in ANCA-associated glomerulonephritis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15901769" id="rid73" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>74 : Membrane proteinase 3 expression in patients with Wegener's granulomatosis and in human hematopoietic stem cell-derived neutrophils.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15284296" id="rid74" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>75 : Circumvention of normal constraints on granule protein gene expression in peripheral blood neutrophils and monocytes of patients with antineutrophil cytoplasmic autoantibody-associated glomerulonephritis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1313124" id="rid75" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>76 : Anti-myeloperoxidase antibodies stimulate neutrophils to damage human endothelial cells.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16014030" id="rid76" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>77 : Human anti-neutrophil cytoplasm autoantibodies to proteinase 3 (PR3-ANCA) bind to neutrophils.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9071707" id="rid77" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>78 : Crosslinking of ANCA-antigens stimulates superoxide release by human neutrophils.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8027554" id="rid78" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>79 : Anti-neutrophil cytoplasmic antibodies engage and activate human neutrophils via Fc gamma RIIa.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8007582" id="rid79" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>80 : Neutrophil activation in vitro and in vivo in Wegener's granulomatosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10027922" id="rid80" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>81 : Interleukin-8: A pathogenetic role in antineutrophil cytoplasmic autoantibody-associated glomerulonephritis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12089369" id="rid81" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>82 : Phosphatidylinositol 3-kinase controls antineutrophil cytoplasmic antibodies-induced respiratory burst in human neutrophils.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15149330" id="rid82" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>83 : Membrane proteinase 3 expression and ANCA-induced neutrophil activation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14675038" id="rid83" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>84 : Proteinase 3 sidesteps caspases and cleaves p21(Waf1/Cip1/Sdi1) to induce endothelial cell apoptosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12191967" id="rid84" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>85 : Neutrophil membrane expression of proteinase 3 (PR3) is related to relapse in PR3-ANCA-associated vasculitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15548565" id="rid85" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>86 : Characterization of the regulation and functional consequences of p21ras activation in neutrophils by antineutrophil cytoplasm antibodies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17667990" id="rid86" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>87 : Leukocyte gene expression signatures in antineutrophil cytoplasmic autoantibody and lupus glomerulonephritis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10966488" id="rid87" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>88 : Upregulation of CD14 and CD18 on monocytes In vitro by antineutrophil cytoplasmic autoantibodies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15610236" id="rid88" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>89 : ANCA-induced neutrophil F-actin polymerization: implications for microvascular inflammation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19699684" id="rid89" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>90 : NETs: a new strategy for using old weapons.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22777766" id="rid90" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>91 : Abnormal conformation and impaired degradation of propylthiouracil-induced neutrophil extracellular traps: implications of disordered neutrophil extracellular traps in a rat model of myeloperoxidase antineutrophil cytoplasmic antibody-associated vasculitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19448636" id="rid91" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>92 : Netting neutrophils in autoimmune small-vessel vasculitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35905194" id="rid92" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>93 : Regulation of NETosis and Inflammation by Cyclophilin D in Myeloperoxidase-Positive Antineutrophil Cytoplasmic Antibody-Associated Vasculitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8738804" id="rid93" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>94 : Proteinase 3, the major autoantigen of Wegener's granulomatosis, enhances IL-8 production by endothelial cells in vitro.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7504599" id="rid94" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>95 : Antibodies to proteinase 3 increase adhesion of neutrophils to human endothelial cells.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8565309" id="rid95" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>96 : Antibodies to proteinase 3 mediate expression of vascular cell adhesion molecule-1 (VCAM-1).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8546138" id="rid96" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>97 : Intraglomerular and interstitial leukocyte infiltration, adhesion molecules, and interleukin-1 alpha expression in 15 cases of antineutrophil cytoplasmic autoantibody-associated renal vasculitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16509455" id="rid97" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>98 : Renal expression of ICAM-1 and VCAM-1 in ANCA-associated glomerulonephritis--are there differences among serologic subgroups?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8353286" id="rid98" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>99 : Human endothelial cells express proteinase 3, the target antigen of anticytoplasmic antibodies in Wegener's granulomatosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7554407" id="rid99" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>100 : Endothelial cells and renal epithelial cells do not express the Wegener's autoantigen, proteinase 3.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9933466" id="rid100" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>101 : Anti-proteinase-3 (PR3) antibodies (C-ANCA) recognize various targets on the human umbilical vein endothelial cell (HUVEC) membrane.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10792617" id="rid101" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>102 : ANCA antigens, proteinase 3 and myeloperoxidase, are not expressed in endothelial cells.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10792641" id="rid102" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>103 : Proteinase 3: A cofactor for the binding of antineutrophil cytoplasm antibodies (ANCA) to endothelial cells?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15327398" id="rid103" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>104 : Wegener's granulomatosis is associated with organ-specific antiendothelial cell antibodies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11035113" id="rid104" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>105 : The soluble endothelial protein C receptor binds to activated neutrophils: involvement of proteinase-3 and CD11b/CD18.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16320351" id="rid105" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>106 : Induction of endothelial cell apoptosis by the binding of anti-endothelial cell antibodies to Hsp60 in vasculitis-associated systemic autoimmune diseases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26597208" id="rid106" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>107 : Complement system activation in ANCA vasculitis: A translational success story?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24179165" id="rid107" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>108 : C5a receptor (CD88) blockade protects against MPO-ANCA GN.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19384329" id="rid108" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>109 : ANCA-associated vasculitis: from bench research to novel treatments.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6978904" id="rid109" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>110 : Suppression of human B lymphocyte function by cyclophosphamide.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10329824" id="rid110" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>111 : Differential B- and T-cell activation in Wegener's granulomatosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29428808" id="rid111" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>112 : Cellular immune regulation in the pathogenesis of ANCA-associated vasculitides.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/36381498" id="rid112" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>113 : The frequency of Treg subsets distinguishes disease activity in ANCA vasculitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9531324" id="rid113" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>114 : Active Wegener's granulomatosis is associated with HLA-DR+ CD4+ T cells exhibiting an unbalanced Th1-type T cell cytokine pattern: reversal with IL-10.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10364903" id="rid114" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>115 : Monocyte activation in patients with Wegener's granulomatosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16567340" id="rid115" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>116 : Persistent T-cell activation and clinical correlations in patients with ANCA-associated systemic vasculitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16837919" id="rid116" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>117 : Persistent expansion of CD4+ effector memory T cells in Wegener's granulomatosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10560675" id="rid117" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>118 : Association of a syndrome resembling Wegener's granulomatosis with low surface expression of HLA class-I molecules.</p>
</a>
</div>
</div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
